Science,
PARP1,
Technology transfer,
ADP,
Health care,
Merck,
Development,
DNA,
ADC,
Partnership,
Jiangsu Hengrui Medicine,
Cancer,
Merck Group,
Patient,
PARP,
Pharmaceutical industry The agreement includes an option to an exclusive license for its innovative Claudin-18.2 antibody drug conjugate (ADC) SHR-A1904.
Key Points:
- The agreement includes an option to an exclusive license for its innovative Claudin-18.2 antibody drug conjugate (ADC) SHR-A1904.
- "Given the high unmet need in oncology, we are excited to work closely with Merck KGaA, Darmstadt, Germany, to bring Hengrui's innovations to cancer patients worldwide," said Frank Jiang, board member and Chief Strategy Officer of Hengrui Pharma.
- "Partnering with Merck KGaA, Darmstadt, Germany, on our PARP franchise is an important milestone on Hengrui's globalization journey.
- Under the terms of the agreement, Merck KGaA, Darmstadt, Germany, will provide Hengrui Pharma with an upfront payment of €160 million.
Retrieved on:
Tuesday, October 17, 2023
Congress,
Jiangsu Hengrui Medicine,
Food,
Hepatocellular carcinoma,
Research,
Standard of care,
BLA,
Death,
Survival,
R,
Liver cancer,
FDA,
ESMO,
Therapy,
Oncology,
Sorafenib,
NDA,
Regulation of tobacco by the U.S. Food and Drug Administration,
European Society for Medical Oncology,
PDUFA,
Progression-free survival,
HCC,
Patient,
Pharmaceutical industry,
Generic drug,
Lancet,
EU Under the terms of the agreement, Elevar will pay Hengrui Pharma up to $600 million of sales milestones and a double-digit percentage royalty on camrelizumab net sales.
Key Points:
- Under the terms of the agreement, Elevar will pay Hengrui Pharma up to $600 million of sales milestones and a double-digit percentage royalty on camrelizumab net sales.
- In May 2023, a new drug application (NDA) for rivoceranib and a biologics license application (BLA) for camrelizumab were submitted to the U.S. Food and Drug Administration (FDA) for the combination of rivoceranib and camrelizumab as a first-line therapy for uHCC.
- In January 2023, the combination was approved in China as a first-line treatment for uHCC.
- Camrelizumab plus rivoceranib significantly prolonged overall survival and progression-free survival, and increased overall response rate versus sorafenib, a standard first-line treatment for uHCC.
Retrieved on:
Tuesday, October 17, 2023
Congress,
Food,
Hepatocellular carcinoma,
Research,
BLA,
R,
FDA,
Sorafenib,
Therapy,
NDA,
Regulation of tobacco by the U.S. Food and Drug Administration,
Responses to the COVID-19 pandemic in September 2022,
PDUFA,
Progression-free survival,
HCC,
Patient,
Pharmaceutical industry,
Generic drug,
Lancet Under the terms of the agreement, Elevar will pay Hengrui Pharma up to $600 million of sales milestones and a double-digit percentage royalty on camrelizumab net sales.
Key Points:
- Under the terms of the agreement, Elevar will pay Hengrui Pharma up to $600 million of sales milestones and a double-digit percentage royalty on camrelizumab net sales.
- Rivoceranib, under the name apatinib (brand name: Aitan®), is developed by Hengrui Pharma in China.
- Elevar and Hengrui Pharma presented CARES-310 study results at the September 2022 ESMO Congress and published them in The Lancet on July 24, 2023.
- Camrelizumab plus rivoceranib significantly prolonged overall survival and progression-free survival, and increased overall response rate versus sorafenib, a standard first-line treatment for uHCC.
